The GntR/VanR transcription regulator AlkR represses AlkB2 monooxygenase expression and regulates n‐alkane degradation in Pseudomonas aeruginosa SJTD‐1

The GntR/VanR transcription regulator AlkR represses AlkB2 monooxygenase expression and regulates n‐alkane degradation in Pseudomonas aeruginosa SJTD‐1

Abstract Transmembrane alkane monooxygenase (AlkB)‐type monooxygenases, especially AlkB2 monooxygenases, are crucial for aerobic degradation of the medium‐to‐long‐chain n‐alkanes in hydrocarbon‐utilizing microorganisms. In this study, we identified a GntR/VanR transcription regulator AlkR of Pseudom...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wanli Peng, Xiuli Wang, Qinchen Liu, Zhihong Xiao, Fulin Li, Nannan Ji, Zhuo Chen, Jiaying He, Junhao Wang, Zixin Deng, Shuangjun Lin, Rubing Liang
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Series:	mLife
Subjects:	AlkB2 monooxygenase AlkR transcription regulator regulatory mechanism structure features VanR–AlkB couples
Online Access:	https://doi.org/10.1002/mlf2.70004
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Structural Analysis of the AlkB Family in Poultry
by: Yuling Niu, et al.
Published: (2025-07-01)

Genome-wide identification and characterization of ALKB homolog gene family in wheat (Triticum aestivum L.)
by: Pengkun Wang, et al.
Published: (2025-03-01)

Revealing the composition of bacterial communities in various oil-contaminated soils and investigating their intrinsic traits in hydrocarbon degradation
by: Mobina Bayatian, et al.
Published: (2025-07-01)

A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01)

<i>N</i>-Alkane Assimilation by <i>Pseudomonas aeruginosa</i> and Its Interactions with Virulence and Antibiotic Resistance
by: Balázs Libisch
Published: (2024-10-01)

Salmonella enterica mediated epigenetic promotion of fibrosis is a novel factor in benign prostatic hyperplasia
by: Cong Zhu, et al.
Published: (2025-05-01)

Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
by: Dafeng Guo, et al.
Published: (2022-12-01)

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01)

Global research trends on ALK-TKIs in non-small cell lung cancer: a bibliometric analysis
by: Yafeng Liu, et al.
Published: (2025-08-01)

Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer
by: Xie J, et al.
Published: (2025-04-01)

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
by: Seema Chugh, et al.
Published: (2025-02-01)

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01)

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
by: Yue Lu, et al.
Published: (2021-11-01)

ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India
by: Ajita Verma, et al.
Published: (2025-01-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

Ensartinib in a primary pulmonary ALK-rearranged mesenchymal neoplasm harboring a novel HMBOX1::ALK fusion: a case report and literature review
by: Qi Liang, et al.
Published: (2025-05-01)

A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review
by: Shuzhe Yang, et al.
Published: (2025-01-01)

An Isolated Cutaneous Relapse in a Known Case of Systemic ALK-Positive Anaplastic Large Cell Lymphoma: A Rare Case Report with Review of Literature
by: Monisha Shetty, et al.

Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China
by: Zhujun Chen, et al.
Published: (2025-07-01)

Промежуточные результаты проспективного рандомизированного сравнительного исследования эффективности программ NHL BFM-90 и СНОЕР у первичных пациентов с ALK-позитивной анапластической крупноклеточной лимфомой
by: Лилия Гамилевна Горенкова, et al.
Published: (2020-07-01)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-10-01)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
by: Luca Mastrantoni, et al.
Published: (2024-01-01)

CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01)

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data
by: Vera Damuzzo, et al.
Published: (2025-05-01)

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
by: Kaili Huang, et al.
Published: (2025-04-01)

Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience
by: Claudia Parisi, et al.
Published: (2024-12-01)

Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
by: Weizhen SUN, et al.
Published: (2024-11-01)

Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
by: Mingyue Wang, et al.
Published: (2025-02-01)

Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
by: Suma Devaraj, et al.

Identifying the Intergenic ALK Fusion LOC388942‐ALK as a Driver of Non–Small Cell Lung Cancer
by: Xiaoqian Zhai, et al.
Published: (2025-04-01)

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01)

Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
by: Simon Heeke, PhD, et al.
Published: (2025-04-01)

The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment—Literature Review
by: Anita Gorzelak-Magiera, et al.
Published: (2024-10-01)

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
by: Federica Malighetti, et al.
Published: (2024-12-01)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
by: Athanasios R Paliouras, et al.
Published: (2020-06-01)

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome
by: Mingyuan Du, et al.
Published: (2024-12-01)

Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
by: Qian Huang, et al.
Published: (2022-09-01)

Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia
by: Peiyao Wang, BSc, et al.
Published: (2025-04-01)

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib
by: Feng Jin, et al.
Published: (2025-06-01)

<i>ALK</i>-Rearranged Renal Cell Carcinoma: A Case Report with Review of Literature
by: Gauri Deshpande, et al.